Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda's Hopes For Replacement Diabetes Drug May Hit U.S. FDA Wall

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical's SYR-322 (alogliptin) diabetes drug, which it was relying on to take the place of one of its best-sellers, may be headed for a four-year delay in getting U.S. FDA approval. The drug maker faces the possibility of having to conduct more clinical trials to determine the drug's contribution to the risk of heart attacks and strokes. An FDA decision on whether to require the tests is considered imminent. Takeda was counting on the drug to be on the market in time to cushion losses when its Actos (pioglitazone) diabetes drug loses U.S. patent protection. (Click here for more
UsernamePublicRestriction

Register

SC072019

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel